![](https://endpts.com/wp-content/uploads/2023/08/AP22173696682458-scaled.jpg)
Leonard Schleifer, Regeneron CEO (Lev Radin/Sipa USA/Sipa via AP Images)
FDA asks for more data on Dupixent in COPD in move that could delay a decision
The FDA wants more info on Regeneron and Sanofi’s blockbuster Dupixent before it decides whether to approve the treatment for some patients with chronic obstructive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.